Merck’s Isentress, the first FDA–approved integrase inhibitor, was the result of more than a decade’s work by Merck researchers who knew that HIV/AIDS patients, especially those for whom current medicines weren’t working, needed a product with a new approach to fighting the disease.
In a marked departure from the past, teams from across Merck – from manufacturing to marketing – worked together earlier than ever before to get Isentress to patients as quickly as possible, without compromising our commitment to safety. They succeeded. Isentress was approved 18 months ahead of schedule, and took less than four years to move from its first clinical trial to FDA approval in October.
Such collaboration is part of a new strategic model at Merck. Now, all those responsible for a product are working together from the earliest research stages throughout its lifecycle.
Getting our new drugs and vaccines to market faster than ever before has never been more important. Our new approach is giving us a real edge – an edge that is already making a difference to Merck and to patients.
Merck.com is best viewed with Adobe Flash.
